Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933055 | 0.85 | ESR1 (0.42) | ESR1ESR2OPRM1NR3C1PGR | |
| SCHEMBL29238209 | 0.84 | ESR1 (0.41) | ESR1ESR2OPRM1NR3C1PGR | |
| SCHEMBL29238161 | 0.84 | ESR1 (0.41) | ESR1ESR2OPRM1NR3C1PGR | |
| SCHEMBL287362 | 0.79 | PPARG (0.48) | HTTMEN1KMT2A | |
| SCHEMBL26379080 | 0.79 | ESR2 (0.49) | ESR1ESR2OPRM1NR3C1PGR | |
| SCHEMBL38096 | 0.78 | KDM4E (0.55) | ESR1ESR2NR3C1PGRNR3C2 | |
| SCHEMBL11593932 | 0.78 | NCEH1 (0.34) | HTTMEN1KMT2ATACR1 | |
| SCHEMBL7941005 | 0.78 | NCEH1 (0.34) | HTTMEN1KMT2ATACR1 | |
| SCHEMBL3450569 | 0.78 | NCEH1 (0.34) | HTTMEN1KMT2ATACR1 | |
| SCHEMBL2177581 | 0.78 | KDM4E (0.55) | ESR1ESR2NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022075354-A1 | A METHOD FOR OBTAINING AN INDEX FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD) | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2022-04-14 | — | — | WO | claimed |
| US-20040029796-A1 | Medicinal uses of mu-opioid receptor agonists | CORNELL RESEARCH FOUNDATION, INC. | 2004-02-12 | — | — | US | claimed |
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | claimed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4347616-A2 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | Eyedea Bio, Llc (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| CN-117752766-A | Methods of treating mitochondrial disorders | 康德生物医疗有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-7541340-B2 | In a cell by contacting cell with an aromatic-cationic peptide having at least one net positive charge, a minimum of four amino acids, a maximum of about twenty amino acids; for example, where aromatic-cationic peptide comprises Phe-D-Arg-Phe-Lys-NH2; reduced Oxidized Low-Density Lipoprotein | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1931369-A2 | METHODS FOR REDUCING CD36 EXPRESSION | Cornell Research Foundation Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070129306-A1 | In a cell by contacting cell with an aromatic-cationic peptide having at least one net positive charge, a minimum of four amino acids, a maximum of about twenty amino acids; for example, where aromatic-cationic peptide comprises Phe-D-Arg-Phe-Lys-NH2; reduced Oxidized Low-Density Lipoprotein | CORNELL RESEARCH FOUNDATION, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007048004-A2 | COMPOUNDS FOR ENHANCING HYPOXIA INDUCIBLE FACTOR ACTIVITY AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007035640-A2 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1625149-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005001023-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | ESR1 4871/4885ESR2 3916/4885OPRM1 3899/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | ESR1 3893/4885ESR2 2896/4885OPRM1 121/4885 |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | ESR1 4822/4885ESR2 1641/4885OPRM1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.